Trump to nominate 'star' to lead HHS

Trump bills latest HHS pick as “star for lower drug prices”

Azar previously served as a high-ranking executive at Eli Lilly, which has repeatedly raised the prices of its drugs, doubling the USA list price of its top-selling insulin over the 5 years he served as a company president. He is a former pharmaceutical executive and worked for Eli Lilly for almost a decade, and became president of Lilly USA in 2012. "I don't think anybody can question his credentials from an experience perspective".

"He will be a star for better healthcare and lower drug prices!" the president tweeted. Investigations into Price's actions are ongoing. Still, drug pricing talk hasn't gotten serious in Congress and four Congressmen wrote to the president last month to say his "inaction" on their Medicare negotiation proposal has left them with no option other than to press ahead alone.

Azar, though a spokesman, declined to comment. Ron Wyden said the president "at every turn. has broken his promises to American families to lower health care costs, expand access and bring down the high price of prescription drugs." Sen.

Alex Azar is the latest Hoosier headed to Washington for a post in the federal health sector.

Azar has also said he is against expanding Medicaid reimbursements, which provide insurance to almost 130 million Americans under the Affordable Care Act, saying that he would prefer to use government money through "private-sector vehicles" in order to provide health care.

"In his public statements, Alex Azar has made clear that he is opposed to measures to restrain prescription companies' profiteering and limit improper marketing, while favoring weaker safety approval standards".

Azar's nomination must be approved by the U.S. Senate, which is controlled by Trump's fellow Republicans. "He had full responsibility as deputy secretary for the regulatory processes at HHS".

Related:

Comments


Other news